GATA2 deficiency and related myeloid neoplasms by Wlodarski MW et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a  
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Wlodarski MW, Collin M, Horwitz MS.  
GATA2 deficiency and related myeloid neoplasms.  
Seminars in Hematology 2017, 54(2), 81-86. 
 
 
Copyright: 
© 2017 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the  
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).  
DOI link to article: 
https://doi.org/10.1053/j.seminhematol.2017.05.002  
Date deposited:   
20/06/2017 
Seminars in Hematology 54 (2017) 81–86Contents lists available at ScienceDirectSeminars in Hematologyhttp://d
0037-19
(http://c
n Corr
Mathild
E-mjournal homepage: www.elsevier.com/locate/enganaboundGATA2 deficiency and related myeloid neoplasms
Marcin W. Wlodarskia,b,n, Matthew Collinc, Marshall S. Horwitzd
a Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology; Medical Center; Faculty of Medicine, University of
Freiburg, Germany
b German Cancer Consortium (DKTK), Freiburg, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany
c Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; Northern Centre for Bone Marrow Transplantation, Newcastle
upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
d Department of Pathology, University of Washington School of Medicine, Seattle, WA, USAa r t i c l e i n f o
Available online 19 May 2017
Keywords:
Genetic predisposition
GATA2 deficiency
Familial MDS
MonoMAC
Emberger syndrome
Monosomy 7
Bone marrow failurex.doi.org/10.1053/j.seminhematol.2017.05.002
63/$/& 2017 The Authors. Published by Elsev
reativecommons.org/licenses/by-nc-nd/4.0/).
esponding author. Marcin Wlodarski, MD, Un
enstr. 1, 79106 Freiburg, Germany. Tel.: þ497
ail address: marcin.wlodarski@uniklinik-freibua b s t r a c t
The GATA2 gene codes for a hematopoietic transcription factor that through its two zinc fingers (ZF) can
occupy GATA-DNA motifs in a countless number of genes. It is crucial for the proliferation and
maintenance of hematopoietic stem cells. During the past 5 years, germline heterozygous mutations
in GATA2 were reported in several hundred patients with various phenotypes ranging from mild
cytopenia to severe immunodeficiency involving B cells, natural killer cells, CD4þ cells, monocytes and
dendritic cells (MonoMAC/DCML), and myeloid neoplasia. Some patients additionally show syndromic
features such as congenital deafness and lymphedema (originally defining the Emberger syndrome) or
pulmonary disease and vascular problems. The common clinical denominator in all reported cohorts is
the propensity for myeloid neoplasia (myelodysplastic syndrome [MDS], myeloproliferative neoplasms
[MPN], chronic myelomonocytic leukemia [CMML], acute myeloid leukemia [AML]) with an overall
prevalence of approximately 75% and a median age of onset of roughly 20 years. Three major mutational
types are encountered in GATA2-deficient patients: truncating mutations prior to ZF2, missense
mutations within ZF2, and noncoding variants in the þ9.5kb regulatory region of GATA2. Recurrent
somatic lesions comprise monosomy 7 and trisomy 8 karyotypes and mutations in SETBP1 and ASXL1
genes. The high risk for progression to advanced myeloid neoplasia and life-threatening infectious
complications guide decision-making towards timely stem cell transplantation.
& 2017 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Since its initial description in 2011, GATA2 deficiency has been
recognized as a major myelodysplastic syndrome (MDS) predis-
position syndrome, with nearly 400 patients reported in several
case series (Table 1). The phenotypic bias of the reported cohorts
with GATA2-related disease exemplifies the clinical heterogeneity
of this transcriptopathy disorder. Previously established clinical
entities known to be caused by GATA2 mutations include mono-
cytopenia and Mycobacterium avium complex (MonoMAC)/den-
dritic cell, monocyte, B and NK lymphoid deficiency (DCML) (MIM
#614172) [1–4], Emberger syndrome (MIM #614038) [5,6], and
familial MDS/acute myeloid leukemia (AML) (MIM 601626 and
614286) [7]. Additional recurrent manifestations include primary
pediatric MDS [8] and chronic neutropenia [9]. However, due toier HS Journals, Inc. This is an ope
iversity of Freiburg, Germany,
61 270 43000.
rg.de (M.W. Wlodarski).considerable phenotypic overlaps in affected patients these enti-
ties are now recognized as a single disorder with pleiotropic
manifestations and high risk for myeloid neoplasia [8,10–12].
Experimental and clinical evidence implicates that loss of function
of GATA2 leads to aberrant hematopoiesis with resulting myeloid
neoplasia, often associated with acquisition of certain cytogenetic
aberrations or somatic gain of function mutations.2. Mechanistic principles
GATA2 is a nuclear regulatory protein, a member of evolu-
tionary conserved family of transcription factors that regulate the
expression of multiple target genes by binding to the consensus
DNA sequence T/A(GATA)A/G located in numerous promoters and
enhancers [13]. GATA1, GATA2, and GATA3 are primarily expressed
in hematopoietic cells [1], whereas GATA4, GATA5, and GATA6 are
mainly restricted to tissues of mesodermal and endodermal origin,
eg, heart and gut [14].n access article under the CC BY-NC-ND license
Table 1
Prevalence of GATA-related myeloid neoplasia.
Year
reported
Author PMID Screening
cohort
No. of GATA2-
mutated cases
No. of cases with
myeloid neoplasia
Age at Dx of myeloid neoplasia;
median (range), years
Monosomy 7
&der(1;7), %
Trisomy
8, %
2011 Hahn7 21892162 Familial MDS/AML 28 15 10–53 (20.5) 50 10
2011 Ostergaard6 21892158 Emberger syndrome 14 8 9–53 (12) 75 0
2012 Bodor*47 22271902 Familial MDS 5 2 18–23 (20.5) 2/2 0
2012 Kazenwadel39 22147895 MDS/AML 10 9 10–33 (16) 44 11
2012 Holme45 22533337 Familial MDS 4 4 12–48 (20) 25 0
2013 Pasquet9 23223431 Chronic neutropenia 14 10 6–35 (15) 70 0
2013 Hsu48 23502222 MonoMAC 32 20 3–78 (21.5) n.a. n.a.
2014 Spinner12 24227816 GATA2 deficiency 57 42 0.4–78 (19) 21 24
2014 West50 24077845 GATA2 deficiency 48 42 12–78 (35.5) 20 22.5
2014 Dickinson41 24345756 GATA2 deficiency 30 11 4–40 (25) 18 18
2015 Mir*42 25619630 Myeloid neoplasms 5 3 7–38 (22.5) 0 0
2015 Ganapathi41 25359990 GATA2 deficiency 28 28 14–60 (30) 23 23
2015 Churpek69 26492932 Familial MDS 7 6 13–68 (16.5) 0 25
2015 Wang51 26022708 Pediatric MDS 6 5 n.a. 80 20
2015 Zhang52 25239263 Pediatric MDS 5 5 12–22 (16) 0 40
2016 Wlodarski8 26702063 Pediatric MDS 60 57 3–19 (12) 75 9
2016 Novakova43 27013649 Pediatric MDS 12 10 4.4–17 (14.5) 80 10
2017 Schlums49 28209719 GATA2 deficiency 13 5 7–60 (18) n.a. n.a.
Total/ avg 378 282 (75%) 19.7 (12–35.5) 41% 15%
Dx ¼ diagnosis; N.a. ¼ data not available.
n Not included in summary statistics for karyotypes due to low number of reported cases.
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chromosome 3 at position 21.3 (3q21.3) and depending on the
isoform, it consists of 6 or 7 exons. Its transcription is initiated
from the first two exons. The proximal IG exon is exploited in all
tissues expressing GATA2, while the distal IS exon is specific for
hematopoietic and neuronal cells [15–17]. GATA2 protein contains
two highly conserved zinc finger domains (C-ZnF and N-ZnF)
responsible for its DNA-binding ability and interaction with other
proteins [13]. Additionally, other non-finger domains are distin-
guished: two transactivation domains, a nuclear localization sig-
nal, and a negative regulatory domain [18,19].
GATA2 is highly expressed in immature hematopoietic cells and
declines with blood cell maturation. It is crucial for the prolifer-
ation and maintenance of hematopoietic stem cells (HSCs) [13,20].
High GATA2 expression was observed in hematopoietic progenitor
cells, early erythroid cells, mast cells, and megakaryocytes [20,21].
However, it is not limited to the hematopoietic lineage, as it can be
expressed in endothelial cells, fetal liver, fetal heart, placenta, and
central nervous system [15,22–24]. GATA2 gene expression is
controlled by a variety of cis-regulatory elements including -77kb
(human -110kb), -3.9kb, -2.8kb, -1.8kb, and þ9.5 kb (containing E-
box regulatory site). Those sites can be occupied by multiple
factors affecting gene transcription. GATA2 can bind itself to the
sites upstream the gene locus leading to positive autoregulation. It
selectively occupies -2.8kb site in the transcriptionally active state
in HSCs and progenitor cells, whereas its displacement by GATA1
in erythromyeloid progenitors results in repression of GATA2
transcription [25,26]. It has been observed that -1.8kb site is
required to restrain GATA2 expression in late-stage erythroblasts
in vivo [27]. This dynamic transition of GATA factors expression
referred as the “GATA switch” plays a critical role in differentiation
of hematopoietic cells. It is responsible for the maintenance of
erythroid homeostasis by the transcriptional regulation of multiple
erythroid genes [28].GATA2
Hemogenic
endothelium
Fig. 1. Mechanistic principles. GATA2 is involved in the emergence of hematopoi-
etic stem cells from hemogenic endothelium. Later, it is essential for the home-
ostasis and proliferation of HSCs, at the expense of proliferation of hematopoietic
progenitor cells (HPCs).3. Role in leukemic transformation
GATA2 plays a pivotal role in HSCs emergence from hemogenic
endothelium in the process called endothelial to hematopoietic
transition (Fig. 1) [29]. Subsequently, it is essential for themaintenance and proliferation of HSCs by the complex interactions
with a network of other hematopoietic transcription factors, eg,
RUNX1, SCL/TAL1, MYB, GFI1, FLI1, LYL1, or PU.1 [21,29]. Balanced
expression of GATA2 is essential for proper hematopoiesis and the
disruption of its structure and/or activity can contribute to
leukemogenesis. GATA2 overexpression is associated with devel-
opment of AML and correlates with poor prognosis [30]. Among
the cases with normal karyotype, GATA2 overexpression coincided
with FLT3-ITD, NPM1 mutations and with WT1 or EVI1 over-
expresson [31]. Somatic GATA2 mutations GATA2 are frequent
(10%) in intermediate-risk karyotype AML with biallelic CEBPA
mutations and are associated with favorable prognosis. Most of the
reported somatic mutations are located within ZF1, with p.
Leu321Phe being the most prevalent [32,33]. Confirmed gain-of-
function mutation p. Leu359Val (ZF2) had been identified in 10% of
cases with chronic myelogenous leukemia (CML) during blast
transformation [34]. Furthermore, it has been reported that
rearrangement of GATA2 distal enhancer -77kb, resulting from
chromosomal aberrations inv(3)(q21q26.2) or t(3;3)(q21;q26.2)
promotes leukemic transformation [35,36]. Through structural
repositioning the regulatory element is displaced into close prox-
imity of EVI1, resulting in its misexpression in hematopoietic stem
M. W. Wlodarski et al. / Seminars in Hematology 54 (2017) 81–86 83and progenitor cells (HSPC). This disengagement leads to
“somatic” GATA2 haploinsufficiency, consequently disrupting
homeostasis of hematopoietic progenitors.
Complete deficiency of GATA2 in a knockout mouse model
results in embryonic lethal phenotype due to failure in initial
blood cell production [21]. Notably, haploid dose of GATA2 in a
haploinsufficient mouse model results in defective HSC production
with a 50% reduction of definitive HSC compartment, without the
development of MDS or leukemia [37,38]. In the setting of human
GATA2 deficiency, it is unclear how germline loss-of-function
mutations result in myeloid neoplasms.4. Hematological presentation of GATA2-related disease
While the common denominator of clinical phenotype are
cytopenias and myeloid neoplasms, the initial presentation can be
variable. Some patients present early in life with cytopenias,
immunodeficiency and hypocellular bone marrow failure, and can
experience severe bacterial and viral infections [4,9,11,39–42]. In
other patients MDS with excess of blasts (MDS-EB) can develop
sporadically without preexisting clinical features or accessory non-
hematological phenotypes pointing towards GATA2 deficiency, and
without family history of MDS, possibly attributed to the fact that
the initial presentation in such cases might be mild and preceding
cytopenias undetected. [7,8,43]. The incidence of GATA2 deficiency
is unkown, however due to the high disease penetrance and
intolerance to deleterious mutations in GATA2 gene (ExAC database:
12 expected, 0 observed loss-of-function mutations), it can be
assumed that the majority of mutation carriers will develop
hematologic or immunologic problems throughout life (in one
study the penetrance was estimated at 90% by the age of 60 years)
[12].
Initial hematologic symptoms can include single lineage cyto-
penias or pancytopenia; however, in contrast to the MonoMAC
phenotype, monocytosis can be the initial presenting sign in
patients who develop GATA2-related MDS [1,8,9,11,12,40–42,44].
In some cases there is evidence of immune dysregulation with
respective manifestations such as autoimmune hemolytic anemia
or immune thrombocytopenia–like manifestation. Morphological
features are also heterogenous and can involve marrow hypocel-
lularity in patients with cytopenas, and normo- to hypercellular
marrow in patients presenting with MDS-EB. Multilineage dyspla-
sia is present in most cases. Other features observed are reticulin
fibrosis, reduced numbers of bone marrow B and natural killer
(NK) cells, and increased numbers of T-cell large granular lym-
phocytes. Most patients develop MDS (refractory cytopenia of
childhood, refractory cytopenia with multilineage dysplasia,
MDS-EB) with high risk of evolution to AML or chronic myelomo-
nocytic leukemia (CMML), while rather small subset presents with
de novo AML [7,8,12,45,46]. The prevalence of myeloid neoplasia
can be estimated at approximately 75% of mutation carriers,
according to the numbers provided in published case series with
approximately 378 mutation carriers (Table 1) [6–9,11,12,39,41–43,
45–51]. The median age at onset of myeloid neoplasia ranges
between 12 and 35.5 years and on average equals 19.7 years
(Table 1). In children and adolescents with primary MDS, GATA2
deficiency accounts for 7% of all cases, and 15% of patients with
MDS-EB. The most common cytogenetic aberrations are monos-
omy 7 or der(1;7)(q10;p10) leading to a monosomy 7q and a
trisomy 1q. Depending on the screening cohort these aberrations
can be present in up to 80% of GATA2-related MDS patients, with
average estimate of 41% (Table 1). Concurrent cytogenetic lesions
in patients with monosomy 7, include trisomy 8, or trisomy 21,
while complex karyotypes are generally not observed. Isolated
trisomy 8 is the second most common cytogenetic category, withprevalence rates up to 40% and a roughly estimated average of 15%
(Table 1). Notably, when investigating consecutive primary MDS
cohorts in children and adolescents, 37% of patients with monos-
omy 7 and 16% of patients with trisomy 8 had an underlying
GATA2 deficiency. In conclusion, monosomy 7 and trisomy 8 kar-
yotypes are associated with GATA2 deficiency and their presence
can serve as diagnostic “red flag” pointing towards underlying
GATA2 deficiency.5. Immunological features of GATA2 deficiency
The immunodeficiency phenotypes initially reported in associ-
ation with GATA2 mutation included warts, atypical mycobacterial
infection, herpes virus infection and fungal disease
[3,4,11,12,40,48]. In addition, GM-CSF antibody negative pulmo-
nary alveolar proteinosis autoimmune cytopenias, panniculitis,
arthritis and hepatitis and may affect up to 10% of patients. Death
from infection or human papillomavirus (HPV) and Epstein–Barr
virus (EBV)-related neoplasia may occur. These presentations have
been referred to as MonoMAC or DCML deficiency to describe the
immunodeficiency arising from a profound mononuclear cytope-
nia that can occur in the absence of MDS or AML, or antecedent by
decades. Key features include a dendritic cell deficiency and
monocytopenia, loss of transitional B cells, absence of CD56bright
NK cells, inverted CD4:CD8 ratio and abundance of terminally
differentiated CD45RAþ CD8þ T cells (so-called T-effector memory
RAþ or TEMRA cells). Overall, the cellular phenotype is remarkably
close to that seen in chronic infection or age-related immunose-
nescence [70]. Generally, immunoglobulin (Ig) is preserved,
although patients can become markedly hypogammaglobulinemic
and be treated as common variable immune deficiency (CVID).
Even those with apparently normal Ig levels may suffer frequent
sinopulmonary infections and derive benefit from Ig infusion
therapy, suggesting that their humoral responses are of poor
quality.
Prior immune deficiency in a patient with MDS is a very strong
indicator that GATA2 mutation may be present [3,4,40]. However,
immune dysfunction is not an invariable feature of GATA2 mutation.
Several cohorts of children and young adults with a high rate of
GATA2-associated MDS have been described who do not have clinical
manifestations of immune dysfunction at the time of diagnosis [7,8].
The question remains open as to whether silent mononuclear cyto-
penia preceded hematological transformation in these cases or
whether abrupt transformation to MDS/AML is possible without any
prodromal signs. It is apparent that long-lived plasma cells, memory
T cells and stable immunoglobulin affords a significant level of
protection to common pathogens, even when bone marrow function
is significantly declining. Therefore, it is not surprising that many
patients remain without infectious complications unless they are
exposed to mycobacterium, H1N1 influenza or other virulent patho-
gen. Moreover, prospective study of healthy family members carrying
GATA2 mutation, indicates that marked and progressive DCML defi-
ciency can be revealed by immunophenotyping whilst the peripheral
blood count remains normal [11]. One study reported that the loss of B
cells and their precursors is the most constant feature of GATA2
deficiency, especially in patients who develop MDS when monocyto-
penia might be masked by progenitor cell expansion and total
lymphocyte counts are maintained by expanding memory T cells [43].
Prospective immunophenotyping of more healthy relatives
carrying familial GATA2 mutation will be required to answer this
question definitively. It is possible that declining mononuclear
cells may prove a useful adjunct for monitoring such unaffected
‘carriers’. The value of progressively elevated Flt3 ligand and clonal
dominance in the bone marrow have also been evaluated in this
context. When a relatively healthy individual is identified with
Fig. 2. Atypical lymphedema manifestation in the preauricular region on the face of a teenage patient diagnosed with GATA2 deficiency.
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and immunosuppressive drugs, and suggest regular monitoring of
pulmonary function.6. Extra-hematopoietic manifestations
There is a wide range of dysmorphic features associated with
GATA2 deficiency [1,4–9,11,12]. These include deafness due to
congenital sensineural defect, hypotelorism, epicanthic folds, long
tapering fingers, neck webbing, behavioral disorder/ADHD, hypo-
thyroidism, urogenital malformations, uni-/bilateral ptosis or
hydrops fetalis. Primary lymphedema is a common feature and
can generally manifest with delayed onset on the limbs or as
testicular hydrocele; however, atypical manifestations can also be
expected, eg, occurring in the face (Fig. 2). As with immunodefi-
ciency, the occurrence of these features in young patients with
MDS should arouse a suspicion of GATA2 mutation.7. Mutational background
To date more than 100 different germline mutations in GATA2
gene had been identified in roughly 400 reported cases
[6–9,11,12,39,41–43,45,47–52]. The mutations are scattered
throughout the gene but essentially three main types can be
specified (Fig. 3). Truncating mutations (stop gain, indel, splice
site) prior or within ZF2 are encountered in roughly 60% of
reported cases, followed by missense mutations within ZF2
detected in 30% of patients. Thirdly, noncoding variants within
intron 4 (NM_032638.4) affecting the þ9.5kb regulatory site
containing E-box and GATA and ETS elements are detected in up
to 10% of patients. Rare aberrations reported in single cases are
whole-gene deletions, in-frame deletions, and missense mutations
C-terminal of ZF2. Additional reported germline variants of
unknown significance (p.Pro41Ala, p.Pro250Ser, p.Pro250Ala) are
located outside relevant protein domains. Thus far, only a handful
of mutations were functionally studied, including p.Thr354Met, p.
Thr355del, p.Ala318Thr, p.Leu321Phe, p.Arg396Gln, p.Thr358Asn,
p.Ala350_Asn351ins8, p.Arg361Leu, p.Cys373Arg, p.Leu321Pro, p.
Pro304His, and p.Arg330X, which are supposed to be loss-of-
function mutations with reduced DNA binding ability and/ortransactivation activity [6,7,33,53–55]. Conversely, somatic GATA2
mutations p.Leu359Val (ZF2) and p.Gly320Asp (ZF1) identified in
adult myeloid malignancies were described as gain-of-function
mutations [33,56]. Considering these findings, there is an urgent
need to perform more mechanistic studies to elucidate the func-
tional consequences of germline GATA2 mutations.
To date, no significant genotype–phenotype association has been
established. Although one study reported a possible association of null
mutations with lymphedema and severe infections [39], this associ-
ation could not be confirmed in other cohort studies [8,57]. It can be
estimated that approximately 20%–30% of all germ-line mutations are
inherited while others occur de novo [8,10].8. Clonal evolution and acquired genetic changes
While roughly 75% of GATA2-deficient patients develop mye-
loid neoplasia (Table 1), the drivers of myeloid transformation are
not entirely known. Concurrent ASXL1 mutations have been
reported in a number of patients with GATA2-related MDS and
were postulated as a collaborating event in the development of
myeloid neoplasia [47,50,58]. However, this association seems to
arise from the bias of monosomy 7, which is the most frequent
karyotype in GATA2-related MDS. When investigating larger
cohorts of patients primary MDS and monosomy 7, there was no
difference in the frequency of ASXL1 mutations between patients
with or without germline GATA2 mutation [59–61]. Other muta-
tions recurrently encountered in GATA2-related MDS are gain-of-
function hotspot SETBP1 mutations [60]. These mutations are
common in AML, CMML, and atypical CML, and they are thought
to act as strong oncogenic drivers [62,63]. Interestingly, analysis of
bone marrow of patients with GATA2-related MDS at the single-
cell level revealed a nonrandom nature of clonal evolution, with
monosomy 7 developing as an early somatic event that seems to
be followed by the acquisition of SETBP1 and ASXL1 mutations
(Pastor and Wlodarski, unpublished observations).
9. Therapy and prognostic considerations
Early diagnosis of GATA2-deficiency should help limiting the use
of non-curative therapies specifically avoiding immunosuppression.
Fig. 3. Mutational spectrum in GATA2 deficiency. Peptide sequence involved in the formation of zinc finger (ZnF) 1 and 2 is shown. The majority of germline mutations are
truncating mutations ocurring prior or within zinc finger 2 (ZnF2) or missense mutations within ZnF2, while noncoding mutations within þ9.5kb regulatory site can be
present in up to 10% of patients.
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GATA2-related advanced MDS due to the underlying immunode-
ficiency and stem cell defect. The high risk for progression to
advanced disease with high-risk karyotypes guides the decision-
making towards timely HSC transplantation (HSCT); however,
there is no clear evidence to advocate for early an HSCT in GATA2
mutation carriers who are phenotypically silent. However, it is
well accepted that HSCT should be performed before the patients
develop MDS-EB with karyotypic abnormalities, severe immuno-
deficiency with systemic infections, or severe lung disease. The
ideal time window for HSCT in GATA2-deficient patients is
considered to be during the phase with marrow hypocellularity
and before manifestation of severe complications (ie, invasive
infections) or development of monosomy 7 and/or blast increase
[64–68].
No reliable estimates exist on the outcomes GATA2-deficient
patients within prospective cohorts. The National Institutes of
Health reported a survival rate of 54% at 4 years after HSCT in 21
GATA2-deficient patients transplanted for myeloid neoplasia or
immunodeficiency [12]. Notably, in pediatric consecutive MDS
cohorts, when examining GATA2 mutational status according to
MDS subtypes, GATA2 mutational status did not confer poor
prognosis [8]. The comparably favorable 5-year overall survival
of 66% in GATA2-deficient children transplanted for MDS with
monosomy 7 likely results from the younger age and the lower
rate of systemic complications. The preparative regimen for HSCT
in GATA2-related MDS can be guided by the known MDS risk
factors such as cytogenetic evolution, severity of cytopenias, and
advanced disease. These considerations support the need for a
close monitoring of patients at risk for the occurrence of any of
these complications, with individually tailored surveillance
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